Ovid Therapeutics Inc. (OVID) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Current obligations | 9.98M USD | Liabilities, Current |
| Cash and equivalents | 11.33M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 105.89M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $9.98M | $11.33M | $105.89M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $15.75M | $94.06M | $61.46M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $8.29M | $13.15M | $56.48M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $6.80M | $20.61M | $4.99M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $8.92M | $28.41M | $9.93M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $9.31M | $21.14M | $21.86M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $10.52M | $26.30M | $26.77M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $11.63M | $15.02M | $47.70M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $14.12M | $29.69M | $47.28M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $8.90M | $30.77M | $59.49M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $11.47M | $27.04M | $78.79M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $8.66M | $57.44M | $29.64M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $10.14M | $71.62M | $24.89M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $6.72M | $63.05M | $54.67M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $6.99M | $44.87M | $84.13M | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | $58.26M | $79.60M | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | $72.81M | $79.55M | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | $166.67M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $14.80M | $187.80M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $10.06M | $201.78M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $11.29M | $212.17M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $16.35M | $233.05M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $22.06M | $72.03M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $17.96M | $86.87M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $14.59M | $41.25M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $9.99M | $27.34M | $31.00M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $10.53M | $41.90M | $34.84M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $10.36M | $37.91M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $9.18M | $47.36M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $8.07M | $54.60M | $5.04M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $8.84M | $36.49M | $5.01M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $10.42M | $30.51M | $21.99M | (m) | (m) | (m) |
| 2018-06-30 | (m) | $7.50M | $22.54M | $40.06M | (m) | (m) | (m) |
| 2018-03-31 | (m) | $6.58M | $29.20M | $44.96M | (m) | (m) | (m) |
| 2017-12-31 | (m) | $6.02M | $87.13M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $4.61M | $96.04M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $7.07M | $106.12M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $4.87M | $44.23M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $3.73M | $51.94M | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | $57.75M | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | $62.45M | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | $66.04M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | $69.94M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | $4.85M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |